Therapeutic efficacy and clinical evaluation of dasatinib

Dasatinib (Dasatinib) is a tyrosine kinase inhibitor (TKI), mainly used to treat hematological tumors such as chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It exerts a therapeutic effect by inhibiting the BCR-ABL fusion protein and other related tyrosine kinases, blocking the proliferation and survival signals of leukemia cells. Compared with early tyrosine kinase inhibitors, such as imatinib (Imatinib), dasatinib has shown stronger efficacy and better resistance in the treatment of certain types of leukemia. When patients use dasatinib, how to evaluate its therapeutic effect and clinical response is an important step to ensure that patients receive the best treatment.

1. Therapeutic effect of dasatinib

Dasatinib is used to treat chronic myelogenous leukemia (CML), especially in patients who are resistant or intolerant to other drugs (such as imatinib). It can effectively inhibit the abnormal tyrosine kinase produced by the BCR-ABL fusion gene, block the proliferation signals of tumor cells, and achieve the purpose of inhibiting the growth of leukemia cells. For patients with CML in the chronic phase, the use of dasatinib can significantly improve clinical response and reduce the risk of disease progression.

In addition, dasatinib is also used in the treatment of acute lymphoblastic leukemia (ALL), especially in BCR-ABL fusion-positive ALL patients, showing good therapeutic effects. Compared with imatinib, dasatinib has a stronger effect on some drug-resistant leukemia patients, especially when overcoming certain mutations (such as the T315I mutation).

2. Evaluation of clinical response

The effectiveness of dasatinib treatment is usually assessed by:

Hematological response: Hematological response is mainly assessed by monitoring the patient's white blood cell count, hemoglobin level, platelet count and other indicators. For CML patients, the hematological response after dasatinib treatment is usually manifested by normalization of the white blood cell count, that is, the number of white blood cells returns to the normal range, which indicates that the leukemia is well controlled. ForALLIn patients, the hematological response includes the reduction of leukemic cells, especially the clearance of BCR-ABL positive cells in the peripheral blood.

Molecular response: Molecular response is an important indicator to evaluate the therapeutic effect of dasatinib, usually through the detection of BCR-ABL fusion gene. This genetic test usually uses quantitative PCR (polymerase chain reaction) technology to detect the presence and level of expression of the BCR-ABL fusion gene in the patient. Clinically, when a patient achieves molecular complete remission (MR4), it means that there is almost no BCR-ABL fusion gene in the body, the treatment effect is significant, and the disease is well controlled. If a molecular response (MR3 or MR4) is achieved, it indicates that the patient has a very positive response to treatment.

Cytological response: Cytological response is assessed by a bone marrow biopsy, which measures the proportion of leukemia cells in the bone marrow. The bone marrow cytological response of patients after dasatinib treatment usually manifests as a decrease in leukemia cells, especially a decrease in BCR-ABL positive cells, which is a key indicator of the effectiveness of treatment.

Clinical remission: Clinical remission refers to the significant relief of the patient's leukemia symptoms, and the clinical manifestations are the reduction or disappearance of leukemia-related signs and symptoms (such as anemia, infection, bleeding, etc.). For CML patients, the acute transformation or accelerated phase of leukemia should be avoided after treatment, so it is very important to regularly check the patient's clinical symptoms and signs.

3. Assessment of adverse reactions and drug resistance during treatment

Although dasatinib is effective in many patients, some adverse reactions may occur during treatment, especially cardiovascular system reactions (such as QT interval prolongation, heart failure, etc.), pulmonary problems (such as pulmonary hypertension), gastrointestinal reactions (such as diarrhea, nausea, vomiting, etc.), and bone marrow suppression. These adverse reactions may affect the continuation of treatment, so the patient's health needs to be closely monitored during treatment.

In addition, with long-term use of dasatinib, some patients may develop drug resistance, which is usually manifested by a weakening of the treatment effect or complete failure. The emergence of drug resistance may be related to BCR-ABL mutations, changes in the pharmacokinetics of the drug, or other resistance mechanisms. Therefore, it is crucial to regularly monitor drug resistance mutations and patients' treatment responses during treatment to help doctors make timely treatment adjustments.

4. Comprehensive assessment and individualized treatment

The efficacy evaluation of dasatinib not only relies on hematological, molecular and cytological responses, but also needs to consider the patient's clinical symptoms, drug resistance and side effects. An individualized treatment plan is the key to ensuring the best treatment effect. Doctors need to develop an individualized treatment plan based on the patient's specific situation (such as leukemia subtype, mutation type, side effects, etc.). For the use of dasatinib, it is necessary to comprehensively consider the efficacy of the drug, the risk of drug resistance, and the patient's health status to ensure that the treatment plan can maximize the efficacy while minimizing the occurrence of side effects.

Dasatinib is a highly effective tyrosine kinase inhibitor that plays an important role in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). By evaluating hematological, molecular, and cellular responses, doctors can determine the effectiveness of treatment and adjust treatment strategies. During the treatment process, patients may experience some side effects and drug resistance, so regular monitoring and individualized treatment adjustments are required to ensure optimal treatment effects and reduce adverse reactions.

Reference materials:https://go.drugbank.com/drugs/DB01254